NCT01218477 - Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Leukemia

Interventions

DRUG

Dasatinib

Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)

DRUG

BMS-833923

Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)

Trial Locations (12)

10043

Local Institution, Orbassano(To)

21287

Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore

33076

Local Institution, Bordeaux

40138

Local Institution, Bologna

60590

Local Institution, Frankfurt am Main

77030

Ut M.D. Anderson Cancer Center, Houston

86021

Local Institution, Poitiers

94143

University Of California Medical Center, San Francisco

L8N 3Z5

Local Institution, Hamilton

M5G 2M9

Local Institution, Toronto

00290

Local Institution, Helsinki

G12 0YN

Local Institution, Glasgow